Search Results - gregory+hudalla

2 Results Sort By:
Galectin Candidate Therapeutic for Modulating Immune Response
Regulates Inflammation and Immune Responses at Lower Doses Than Other Galectin Therapeutics This fusion protein is composed of galectin-1 and galectin-3 and is a candidate therapeutic for modulating immune responses and treating inflammation. The global autoimmune disease therapeutics market should reach $1.5 billion by 2025. Galectins are promising...
Published: 1/20/2026   |   Updated: 11/18/2021   |   Inventor(s): Gregory Hudalla, Margaret Fettis
Keywords(s):  
Category(s): Technology Classifications > Research Tools > Therapeutics
More Stable and Potent Galectin-1 Homodimer for Therapeutic Use in Inflammatory Diseases
Potently Modulates the Immune Response in Autoimmune and Chronic Inflammatory Disease Conditions This polymer crosslinked, more stable Galectin-1 homodimer suppresses inflammation more potently than unmodified recombinant Galectin-1. Galectin-1 (Gal1) modulates innate and adaptive immunity by regulating dendritic cell migration, inducing activated...
Published: 1/20/2026   |   Updated: 6/25/2021   |   Inventor(s): Margaret Fettis, Gregory Hudalla
Keywords(s): galectin, immune modulation, Immunotherapy, Inflammation Reduction, Lymphocytes, Oxydation, Pegylation, Protein Therapy
Category(s): Technology Classifications > Engineering > Materials, Technology Classifications > Human Health Care > Drug Delivery, Technology Classifications > Human Health Care > Therapeutics